Aimee Ledesma, MD
Family Medicine · Pleasant Prairie, WINPI 1033166970
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$597
- Johnson & Johnson$258
- AstraZeneca$220
- Pfizer$206
- AbbVie$175
- Lilly USA, LLC$151
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,671100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $597 |
| Johnson & Johnson | 26 | $258 |
| AstraZeneca | 13 | $220 |
| Pfizer | 10 | $206 |
| AbbVie | 13 | $175 |
| Lilly USA, LLC | 9 | $151 |
| E.r. Squibb & Sons, L.L.C. | 7 | $128 |
| Supernus Pharmaceuticals, Inc. | 7 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $98 |
| Amarin Pharma, Inc. | 4 | $81 |
| Aimmune Therapeutics, Inc. | 3 | $80 |
| Biohaven Pharmaceuticals, Inc. | 2 | $71 |
| Exact Sciences | 3 | $69 |
| Astellas Pharma US Inc | 2 | $51 |
| GSK | 2 | $39 |
| Boehringer Ingelheim | 2 | $35 |
| Dynavax Technologies Corporation | 1 | $34 |
| IBSA Pharma Inc. | 2 | $32 |
| Amgen | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Recor Medical Inc | 1 | $22 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
How this compares
$2,671 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $54,178 |
| XareltoRivaroxaban | 46 | $34,316 |
| JanuviaSitagliptin Phosphate | 33 | $28,165 |
| TrulicityDulaglutide | 16 | $22,577 |
| MounjaroTirzepatide | 13 | $17,782 |
| OzempicSemaglutide | 11 | $12,455 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $7,485 |
| Lisdexamfetamine Dimesylate | 21 | $5,554 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $4,753 |
| Levothyroxine Sodium | 295 | $3,519 |
| Novolog FlexpenInsulin Aspart | 13 | $3,253 |
| Ezetimibe | 144 | $3,191 |
| SynthroidLevothyroxine Sodium | 50 | $2,709 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,483 |
| Atorvastatin Calcium | 248 | $2,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $206 | $54,17872 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $151 | $40,35929 claims |
| Johnson & JohnsonXarelto | $258 | $34,31646 claims |
| Novo NordiskOzempic | $597 | $12,45511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $26 | $7,48511 claims |
| AbbVieSynthroid | $175 | $2,70950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Pleasant Prairie
- Daisy AndaleonPleasant Prairie$11K
- Michelle GauthierPleasant Prairie$9K
- George PoullettePleasant Prairie$6K
- Jennifer ParsleyElk Mound$1.4M
- William PalinMilwaukee$693K
- Ryan AndrewsStevens Point$429K
- Tara DallDelafield$230K
- Mark JensonGreen Bay$204K
- James SamuelMount Pleasant$203K
- Daniel DuffyCedarburg$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.